IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
IDEAYA Biosciences (Nasdaq: IDYA) has announced its upcoming 10-Year Anniversary R&D Day, scheduled for September 8, 2025, from 8:00 AM to 10:00 AM ET in New York City. The event will be accessible both in-person and virtually.
The R&D Day will feature presentations of multiple clinical data updates across the company's pipeline, along with discussions about future growth drivers and upcoming milestones. The event will include presentations from IDEAYA's senior leadership team and key opinion leaders in precision medicine oncology.
CEO Yujiro S. Hata will outline the company's strategic vision, priority scientific focus areas, and emerging clinical pipeline as IDEAYA positions itself as a global leader in precision medicine oncology.
IDEAYA Biosciences (Nasdaq: IDYA) ha annunciato il suo prossimo R&D Day per il 10° anniversario, previsto per il 8 settembre 2025, dalle 8:00 alle 10:00 ET a New York City. L'evento sarà disponibile sia in presenza che virtualmente.
Durante il R&D Day saranno presentati aggiornamenti su diversi dati clinici relativi alla pipeline dell'azienda, insieme a discussioni sui futuri driver di crescita e le prossime tappe importanti. Interverranno il team di leadership senior di IDEAYA e importanti esperti di medicina di precisione oncologica.
Il CEO Yujiro S. Hata illustrerà la visione strategica dell'azienda, le aree scientifiche prioritarie e la pipeline clinica emergente, mentre IDEAYA si posiziona come leader globale nella medicina di precisione oncologica.
IDEAYA Biosciences (Nasdaq: IDYA) ha anunciado su próximo Día de I+D por el 10º aniversario, programado para el 8 de septiembre de 2025, de 8:00 a 10:00 AM ET en la ciudad de Nueva York. El evento será accesible tanto en persona como de forma virtual.
El Día de I+D incluirá presentaciones con múltiples actualizaciones de datos clínicos a lo largo del pipeline de la compañía, además de discusiones sobre futuros motores de crecimiento y próximos hitos. El evento contará con presentaciones del equipo de liderazgo senior de IDEAYA y líderes de opinión clave en oncología de medicina de precisión.
El CEO Yujiro S. Hata expondrá la visión estratégica de la compañía, las áreas científicas prioritarias y la pipeline clínica emergente, mientras IDEAYA se posiciona como líder global en oncología de medicina de precisión.
IDEAYA 바이오사이언시스(Nasdaq: IDYA)는 2025년 9월 8일 오전 8시부터 10시(동부시간)까지 뉴욕시에서 열리는 10주년 연구개발(R&D) 데이 행사를 발표했습니다. 해당 행사는 현장 참석과 온라인 모두에서 참여할 수 있습니다.
R&D 데이에서는 회사의 파이프라인 전반에 걸친 다양한 임상 데이터 업데이트가 발표되며, 향후 성장 동력과 다가오는 주요 이정표에 대한 논의가 진행됩니다. IDEAYA의 고위 경영진과 정밀 의학 종양학 분야의 주요 의견 리더들이 발표에 참여합니다.
CEO 유지로 S. 하타는 회사의 전략적 비전, 우선 과학 분야 및 신흥 임상 파이프라인을 설명하며 IDEAYA가 정밀 의학 종양학 분야의 글로벌 리더로 자리매김하는 모습을 제시할 예정입니다.
IDEAYA Biosciences (Nasdaq : IDYA) a annoncé sa prochaine Journée R&D pour son 10e anniversaire, prévue le 8 septembre 2025, de 8h00 à 10h00 ET à New York. L'événement sera accessible à la fois en présentiel et en virtuel.
La Journée R&D comprendra des présentations de plusieurs mises à jour de données cliniques concernant le pipeline de l'entreprise, ainsi que des discussions sur les futurs moteurs de croissance et les étapes à venir. Des présentations seront faites par l'équipe de direction senior d'IDEAYA ainsi que par des leaders d'opinion clés en oncologie de médecine de précision.
Le PDG Yujiro S. Hata exposera la vision stratégique de l'entreprise, les domaines scientifiques prioritaires et le pipeline clinique émergent, alors qu'IDEAYA se positionne comme un leader mondial en oncologie de médecine de précision.
IDEAYA Biosciences (Nasdaq: IDYA) hat seinen bevorstehenden 10-jährigen Jubiläums-R&D-Tag angekündigt, der für den 8. September 2025 von 8:00 bis 10:00 Uhr ET in New York City geplant ist. Die Veranstaltung wird sowohl vor Ort als auch virtuell zugänglich sein.
Der R&D-Tag umfasst Präsentationen mit mehreren klinischen Datenupdates aus der Pipeline des Unternehmens sowie Diskussionen über zukünftige Wachstumstreiber und bevorstehende Meilensteine. Präsentationen werden vom Senior-Management-Team von IDEAYA und wichtigen Meinungsführern im Bereich der Präzisionsmedizin-Onkologie gehalten.
CEO Yujiro S. Hata wird die strategische Vision des Unternehmens, die prioritären wissenschaftlichen Fokusbereiche und die aufstrebende klinische Pipeline vorstellen, während IDEAYA sich als globaler Marktführer in der Präzisionsmedizin-Onkologie positioniert.
- None.
- None.
"This year marks IDEAYA's ten-year anniversary since our founding, and we look forward to providing multiple clinical data updates across our potential first-in-class pipeline, and highlight our strategic vision, priority areas of scientific focus, and emerging clinical pipeline that will drive the next phase of our growth as a global leader in precision medicine oncology," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.
Speakers will include members of IDEAYA's senior leadership team and key opinion leader(s).
Registration for this event can be accessed here or at the investors section of the IDEAYA website at https://ir.ideayabio.com/events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at a certain investor relation event. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-10-year-anniversary-rd-day-on-september-8-2025-to-present-multiple-clinical-data-updates-and-outline-future-growth-strategy-302510199.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) R&D Day 2025 and how can investors attend?
What will be presented at IDEAYA Biosciences' (IDYA) 2025 R&D Day?
Who will be speaking at IDEAYA's (IDYA) 2025 R&D Day?
How can I access IDEAYA Biosciences' (IDYA) R&D Day presentation?
